# CTRL Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ctrl-therapeutics

- Industry: Biotechnology
- Headquarters: Chicago, US
- Website: www.ctrl-therapeutics.com
- Total disclosed funding: $17M
- Latest round: Series A (Sep 19, 2024)
- Investors on record: 3

## About

Based in Illinois, US, and founded in 2022, CTRL Therapeutics Inc. is a biotechnology company that develops a platform for next-generation cell therapy that can treat a variety of solid cancers. Shana Kelley is the founder and CTO of the company. In April 2023, CTRL Therapeutics Inc. raised USD 10 million in seed funding from General Catalyst, including Intermountain Healthcare, FACIT X, and other investors. As of 2023, the company also has an office in Canada.

The company is developing a patented technology that can extract circulating tumor-reactive lymphocytes (cTRLs) from blood to meet the unmet needs related to cell therapy. The firm’s technology can be used to treat a variety of solid tumours, and it has the potential to open new possibilities for solid tumour cell treatment. CTRL's approach enables the non-invasive extraction of cTRLs from a patient's blood, which simplifies manufacturing and increases cost-effectiveness.

The organization plans to use the April 2023 funding to further develop its technology platform and expand its team.

## Funding rounds

- Series A, Sep 19, 2024, $9.1M — Fight Against Cancer Innovation Trust
- Seed, Oct 12, 2022, $7.5M — General Catalyst Partners, Intermountain Healthcare, Fight Against Cancer Innovation Trust

## Investors

- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Seed
- Intermountain Healthcare — Seed
- Fight Against Cancer Innovation Trust (https://capitalatlas.ai/funds/fight-against-cancer-innovation-trust) — Seed, Series A